As with any medication, discontinuing semaglutide can result in withdrawal symptoms, which might pose challenges for patients
However, the findings provide encouraging evidence that injectable semaglutide may emerge as a promising therapeutic option for women with PMOS seeking improvements in both metabolic and reproductive health.
In an aspect of the present invention, the expressed semapeptide can be cleaved enzymatically in vivo or in vitro (using either pure or partially purified fusion specific protease) by cleavage enzyme which cleaves at the junction between ubiquitin fusion tag and semapeptide to generate the semapeptide
According to the MHRA/EMC Summary of Product Characteristics, semaglutide has a half-life of approximately one week, meaning that within 45 weeks of your last dose, the medication will be largely eliminated from your system
Although semaglutide can lead to impressive weight loss, its important to manage expectations from the beginning
